New inhaled drug aims to help PAH patients walk farther
NCT ID NCT07481981
First seen Mar 29, 2026 · Last updated May 15, 2026 · Updated 9 times
Summary
This study tests a new inhaled powder called treprostinil palmitil (TPIP) taken once daily to see if it helps people with pulmonary arterial hypertension (PAH) walk farther. About 344 adults with PAH will receive either TPIP or a placebo for 24 weeks. The main goal is to measure changes in a 6-minute walk test.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.